BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25212460)

  • 21. Expression of α2,6-sialic acid-containing and Lewis-active glycolipids in several types of human ovarian carcinomas.
    Tanaka K; Mikami M; Aoki D; Kiguchi K; Ishiwata I; Iwamori M
    Oncol Lett; 2010 Nov; 1(6):1061-1066. PubMed ID: 22870113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
    Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
    Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
    Khin EE; Kikkawa F; Ino K; Suzuki T; Shibata K; Kajiyama H; Tamakoshi K; Mizutani S
    Int J Gynecol Pathol; 2003 Apr; 22(2):175-80. PubMed ID: 12649673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic responses of sulfatide and related glycolipids in Madin-Darby canine kidney (MDCK) cells under osmotic stresses.
    Niimura Y; Nagai K
    Comp Biochem Physiol B Biochem Mol Biol; 2008 Jan; 149(1):161-7. PubMed ID: 17905621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosynthesis and biological function of sulfoglycolipids.
    Honke K
    Proc Jpn Acad Ser B Phys Biol Sci; 2013; 89(4):129-38. PubMed ID: 23574804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P73 gene expression in ovarian cancer tissues and cell lines.
    Chen CL; Ip SM; Cheng D; Wong LC; Ngan HY
    Clin Cancer Res; 2000 Oct; 6(10):3910-5. PubMed ID: 11051237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
    Wang J; Cai J; Han F; Yang C; Tong Q; Cao T; Wu L; Wang Z
    Int J Gynecol Cancer; 2011 Aug; 21(6):981-7. PubMed ID: 21738044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers.
    Xia Z; Cochrane DR; Tessier-Cloutier B; Leung S; Karnezis AN; Cheng AS; Farnell DA; Magrill J; Schmidt D; Kommoss S; Kommoss FKF; Kommoss F; McAlpine JN; Gilks CB; Koebel M; Rabban JT; Huntsman DG
    Hum Pathol; 2019 Oct; 92():39-47. PubMed ID: 31220479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
    Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis.
    Määttä M; Bützow R; Luostarinen J; Petäjäniemi N; Pihlajaniemi T; Salo S; Miyazaki K; Autio-Harmainen H; Virtanen I
    J Histochem Cytochem; 2005 Oct; 53(10):1293-300. PubMed ID: 15923364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
    Guo DH; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
    [No Abstract]   [Full Text] [Related]  

  • 38. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
    Zhang MZ; Qiao YH; Suo ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
    Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
    Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas.
    Shimizu M; Nikaido T; Toki T; Shiozawa T; Fujii S
    Cancer; 1999 Feb; 85(3):669-77. PubMed ID: 10091740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.